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Over the last decade, there have been substantial advances in our understanding about how 89 
viral infections regulate asthma (Table 1).  Important lessons have been learned from birth 90 
cohort studies examining viral infections and subsequent asthma, understanding the 91 
relationships between host genetics and viral infections, the contributions of respiratory viral 92 
infections to patterns of immune development, the impact of environmental exposure on severity 93 
of viral infections, and how the viral genome influences host immune responses to viral 94 
infections.  Further, there has been major progress in our knowledge about how bacteria 95 
regulate host immune responses in asthma pathogenesis.  In this article, we also examine the 96 
dynamics of respiratory tract bacterial colonization during viral upper respiratory tract infection, 97 
in addition to the relationship of the gut and respiratory microbiomes with respiratory viral 98 
infections.  Finally, we focus on potential interventions that could decrease virus-induced 99 
wheezing and asthma.  There are emerging therapeutic options to decrease severity of 100 
wheezing exacerbations caused by respiratory viral infections.  Primary prevention is a major 101 
goal and a strategy toward this end is considered. 102 
 103 
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The viral genome and how it influences host immune responses to viral infections 141 
Respiratory syncytial virus (RSV) and rhinovirus (RV) are important causes of wheezing 142 
in early life and wheezing illness with these viruses have been associated with increased 143 
asthma risk later in childhood.  At age 6, there is an increased risk of asthma if children had 144 
wheezing illness with RSV (odds ratio 2.6), RV (odds ratio 9.8), or both RSV and RV (odds ratio 145 
10.0) in the first 3 years of life.  RSV is a negative-sense, single stranded RNA virus that is a 146 
member of the Paramyxoviridae family and is the leading cause of hospitalization each year in 147 
the United States in children under 1 year of age.1 There are three species of RV in the 148 
enterovirus genus, and all are positive-sense, single-stranded RNA viruses that have protein 149 
capsids. RV are the most frequently detected viruses in wheezing children over the age of 1 150 
year, and from children and adults with acute exacerbations of asthma. 151 
The clinical manifestations of a viral infection in the respiratory tract result from a 152 
complex interplay of the host, environment, and virus.  To make comparisons between different 153 
immune responses elicited by diverse viruses, host and the environmental conditions must be 154 
held constant in order to prevent the introduction of confounding factors.  This requires artificial 155 
conditions, such as the use of human cell lines for in vitro infection studies, the infection of 156 
genetically identical animals, such as mice, housed in the same environment, and the use of a 157 
standard viral inoculum.  Determining the effect of specific genes within a virus requires that all 158 
other viral genes are identical.  Such studies have begun but are still relatively new.     159 
Experiments in models of RSV genomes have provided important insights into how the 160 
viral genome influences host immune responses to infection.  Three RSV strains commonly 161 
used in pathogenesis studies are A2, line 19, and Long.  RSV A2 infection in BALB/c mice 162 
resulted in a predominant IFN-γ immune response, no production of the Th2 cytokine IL-13 in 163 
the lung, an absence of airway mucus, and no airway responsiveness (AR) to methacholine.2  164 
Infection with RSV Long similarly did not result in host IL-13 production in the lung nor was there 165 
airway mucus.3  However, line 19 infection in genetically identical mice in the same environment 166 
caused the host immune response to produce IL-13, decreased IFN-γ compared to A2 infection, 167 
airway mucus, and heightened AR.2    Sequencing of the A2, line 19, RSV Long strains revealed 168 
six amino acid differences between line 19 and the A2 and Long strains, of which 5 amino acid 169 
differences were in the fusion (F) protein.3  To determine the contribution of the F gene of each 170 
virus to disease pathogenesis, a reverse genetics approach was undertaken by creating 171 
chimeric viruses whereby an A2 virus was manipulated to replace the A2 F gene with either the 172 
F gene of either line 19 or Long.  Infection with the chimeric virus containing the line 19 F gene 173 
caused decreased host IFN-α lung levels, higher viral load in the lungs, greater lung IL-13 174 
protein, augmented airway mucus, and increased AR, compared to the chimeric viruses 175 
containing either A2 or Long F proteins.3  Therefore, this reverse genetic approach provided the 176 
opportunity to not only discover which genes in RSV line 19 strain were responsible for the lung 177 
IL-13, airway mucus, and AR, but also the identification of the specific amino acids that caused 178 
airway remodeling.  These techniques not only provide the knowledge of unique components of 179 
the viral genome that contribute to specific pathogenic features but may also assist in vaccine 180 
and therapeutic strategies aimed at the proteins responsible for specific disease characteristics. 181 
Future perspectives: To date, there have not been studies that reveal a relationship between 182 
RSV genotypes and the presence of wheezing in hospitalized children with bronchiolitis or 183 
bronchopneumonia; however, this may be a function of the lack of application of technology to 184 
sequence strains because of cost.  Studies relating viral genetics to severity of illness in mice 185 
have demonstrated the intricate interactions between viral genome, viral proteins, host cell 186 
function and metabolism and immune response. Developing a greater understanding of this 187 
chain of events could highlight several therapeutic opportunities, including identification of high-188 
priority pathogens, inhibition of viral or host proteins that are critical for replication, and 189 
strategies to inhibit virus-induced skewing of immune responses that favors viral replication over 190 
host defense. 191 
 192 
Host genetics and viral respiratory infections 193 
 A number of studies have begun to shed light on the relationships among host genetics, 194 
viral infections and acute and long-term respiratory outcomes.  Candidate gene approaches 195 
have been utilized to identify associations between genetic polymorphisms and viral respiratory 196 
illness outcomes. Polymorphisms in several antiviral and innate immune genes have been 197 
linked to susceptibility to respiratory viruses, infection severity, and virus-induced asthma 198 
exacerbations, and have been replicated across multiple cohorts (Table 2). These genes 199 
include STAT4, JAK2, MX1, VDR, DDX58, and EIF2AK2.4 Additionally, whole exome 200 
sequencing has been utilized to identify rare variants in innate immune responses linked to 201 
severe respiratory viral infections. Autosomal recessive IRF7 deficiency has been observed in 202 
one patient in association with severe influenza infection and acts through impairment of 203 
interferon amplification.5 Dominant negative loss-of-function variants in IFIH1, critical to viral 204 
RNA sensing, have been shown to be a risk for intensive care unit hospitalization due to viral 205 
infections in previously healthy children.6 206 
A number of polymorphisms have been specifically associated with increased severity of 207 
illnesses associated with hospitalization from RSV infection. A candidate gene approach 208 
identified SNPs in the innate immune genes VDR, IFNA5, and NOS2 as risk factors for RSV 209 
bronchiolitis.7 In order to further elucidate associations of host genetics with RSV illness severity 210 
and asthma risk, a recent review examined overlap amongst genes associated with both 211 
outcomes. This approach identified a number of genes involved with both innate immunity and 212 
type 2 (Th2) inflammatory responses (ADAM33, IL4R, CD14, TNF, IL13 and IL1RL1) that are 213 
highly relevant to these outcomes.8  214 
The most replicated association between host genetics and asthma risk is the 17q21 215 
locus. In two birth cohort studies, variants in this locus, including ORMDL3 and GSDMB, were 216 
also associated with increased risk of wheezing with RV infections in early life.9 Interestingly, 217 
these variants were only associated with increased risk of subsequent asthma in children who 218 
developed RV wheezing in the first 3 years of life. In contrast, early life RSV wheezing was not 219 
linked to 17q21 variants in these cohorts. In addition, farm exposures10 and pets11 in the home 220 
lessen the risk of asthma for children with high-risk 17q21 genotypes. In each case, the genetic 221 
risk associated with 17q21 was buffered by protective environmental exposures. 222 
RV virulence varies by species; RV-A and RV-C are more likely to cause illnesses, 223 
wheezing and lower respiratory tract infection compared to RV-B,12 which has a slower rate of 224 
replication and induces muted cytokine and chemokine responses.13 Whether there are 225 
individual types within RV species that are more virulent is unknown, and difficult to study given 226 
the genetic diversity of these viruses and high mutation rate.  A functional polymorphism in 227 
cadherin-related family member 3 (CDHR3) has been associated by genome wide association 228 
study (GWAS) with early childhood asthma and severe wheezing episodes.14 Interestingly, 229 
CDHR3 is a receptor that enables binding and replication of RV-C, suggesting that this link 230 
between CDHR3 and asthma risk may be mediated by RV-C infections.15 In support of this 231 
hypothesis, children with the risk polymorphism in CDHR3 were recently found to have greater 232 
risk of RV-C illnesses, but not illnesses associated with other viruses.16 233 
Future perspectives: These genetic associations among respiratory virus susceptibility, infection 234 
severity and subsequent asthma risk may prove to be important to risk stratify populations, and 235 
potentially provide new therapeutic targets for reducing illness severity and subsequent risk. 236 
Further, unbiased approaches have been employed recently to identify pathways of gene 237 
expression in the upper airway that differentiate a viral cold that resolves from one that leads to 238 
an asthma exacerbation.1  Efforts are ongoing to understand how these gene expression 239 
patterns are regulated in hopes of identifying new personalized therapeutic strategies to prevent 240 
asthma exacerbation. The integration of multiple “omics” approaches holds promise to provide 241 
the ability to unravel these complex relationships. 242 
 243 
Environmental factors affecting the inception and severity of asthma exacerbations 244 
The exposome, defined as the measure of all exposures that influence the health of an 245 
individual, is an important determinant of asthma risk during the lifespan of an individual.17 Early 246 
exposures can set in motion pathways that will ultimately define illnesses and symptom 247 
exacerbations, which is especially true when considering the ontogeny of asthma.  From birth 248 
through school years, children are frequently exposed to a variety of respiratory pathogens, 249 
allergens, microbes and airway irritants.  The pathogenic or beneficial effects of these 250 
exposures and their interactions remain the focus of research to develop new interventions and 251 
preventive therapies.  252 
Most of the initial research devoted to the ontogeny of asthma focused on RSV infections 253 
which are frequently detected by culture and tests for RSV antigen in nasal washes from 254 
wheezing infants during the mid-winter months. Studies in the past reported that flares of 255 
wheezing caused by RSV leading to hospitalization during infancy increased the risk for 256 
developing asthma and allergy.18, 19 However, recent studies indicate that the more severe 257 
episodes (i.e., those requiring hospitalization) of infantile wheezing caused by RSV increase the 258 
risk for subsequent wheeze in infants and toddlers, but it is less certain whether RSV-induced 259 
wheeze influences the development of atopy or asthma as children grow older.20  260 
In contrast, flares of wheezing caused by RV are more strongly linked to persistent 261 
wheezing and the development of asthma, especially in children who are sensitized to allergens 262 
at an early age.21-23 In keeping with this, the dominant risk factors for asthma attacks that require 263 
hospital care among children after 3 years of age is the combination of allergic airway 264 
inflammation and RV infection.24-26 As a result, several host factors should be considered in 265 
efforts to treat asthma exacerbations more effectively and to reduce the risk for asthma 266 
development, For example:  267 
1) There may be phenotypes of asthmatic children who would benefit from development of 268 
vaccines to RV or RSV. For example, genetic variations at the 17q21 locus and a coding 269 
SNP in CDHR3 (the receptor for RV-C genotypes) increase the risk for wheezing with 270 
RV during childhood.9, 14  271 
2) There is current interest in whether the administration of a biologic such as omalizumab 272 
(anti-IgE antibody) during early childhood will have a disease modifying effect after this 273 
intervention is discontinued (i.e., the Preventing Asthma in High Risk Kids (PARK) trial; 274 
NCT02570984). 275 
3) There is evidence that the asthmatic airway, especially epithelial cells and innate 276 
lymphoid cells, has a Type 2 bias with enhanced production of TSLP, IL-13, and IL-25 in 277 
parallel with decreased type I and III IFN responses that are needed for effective anti-278 
viral killing and clearance.27-34 This bias may increase the susceptibility of allergic 279 
asthmatics to RV infections.  Once infected, however, in vivo studies have shown that 280 
during RV infections viral loads and clearance are similar among children and young 281 
adults with asthma compared to non-allergic individuals without asthma.31 At present, 282 
mechanisms to explain these differences are poorly understood. A better understanding 283 
is likely to come from research focused on the cascade of early, innate cellular and 284 
molecular events that follow RV infection of epithelial cells. 285 
Future perspectives: Airway inflammation caused by recurrent infections (predominantly with 286 
RV) in the allergic host will continue to be the focus of research designed to develop new 287 
therapies to help children and young adults with asthma. Whether treatments targeting allergic 288 
inflammation will be sufficient to reduce the frequency and severity of exacerbations (e.g., using 289 
new monoclonal antibody-based biologics), or whether additional therapeutics will be needed to 290 
decrease the frequency of RV infections, or enhance viral killing, remains to be determined. 291 
Looking to the future, the evaluation of other interventions such as the administration of 292 
antibiotics to treat secondary bacterial pathogens, or azithromycin to reduce wheezing following 293 
virus infection also deserve further study, along with investigations to determine whether the 294 
administration of vitamin D, probiotics, and dietary modifications (e.g., fish oil) will have benefits. 295 
In contrast, the adverse effects of airway irritants such as environmental tobacco smoke (ETS) 296 
and air pollution (e.g., diesel fuel) on the severity and persistence of RV-induced asthma remain 297 
poorly understood. 298 
 299 
Effects of respiratory viral infections on patterns of immune development 300 
Acute wheezing illnesses with respiratory tract viruses in infancy and early childhood 301 
represent an important risk factor for childhood recurrent wheezing and later asthma 302 
development. This link is particularly well-established with RV and RSV, suggesting that these 303 
viruses may have a causative role, and significant research is directed towards understanding 304 
how these viruses can alter immune development to contribute to asthma pathogenesis. That 305 
said, causation remains unproven and asthma prevention strategies targeting viral illnesses do 306 
not currently exist. 307 
RV-associated wheezing, in particular, is associated with a higher asthma risk than other 308 
viruses; this has been consistently demonstrated across multiple studies.21, 23, 35-38 Many of 309 
these studies have linked RV-induced wheezing with other asthma risk factors, in particular 310 
markers of atopy including allergic sensitization, increased eosinophils, and atopic eczema, 311 
suggesting possible additive or synergistic effects in increasing asthma risk. Experimental 312 
models have demonstrated alterations in type-2 immune responses to RV that may account for 313 
this risk (Figure 1). Mouse models have demonstrated that neonatal RV (RV1B) infection results 314 
in persistent airway hyperresponsiveness, mucous cell metaplasia, and IL-13 production that 315 
does not occur in adult mice. Furthermore, knockout of IL4R prevents this response, consistent 316 
with an IL13-dependent process.39 Subsequent work demonstrated that RV infection leads to 317 
expression of epithelial derived cytokines IL-25, IL-33, and TSLP and an increase in ILC2s as 318 
an important source of airway IL-13; blocking these pathways with anti-IL-25 attenuates 319 
neonatal RV-induced AHR and mucous cell metaplasia.40, 41 While there is no equivalent human 320 
evidence regarding the immune effects of RV in early life, these same pathways are known to 321 
play a key role in the response to RV leading to exacerbations in established asthma.29  322 
A key question however, is whether underlying Th2 inflammation or RV associated 323 
wheezing comes first. A prospective birth cohort analysis has shown that allergic sensitization 324 
generally precedes RV wheezing but not the other way around, suggesting allergic sensitization 325 
may lead to more severe RV illnesses and the development of asthma.42 Supporting this 326 
observation, in vitro studies have shown that Th2 inflammation can inhibit type I and III 327 
interferon antiviral responses to RV infections,43, 44 which may increase susceptibility to more 328 
severe RV infections. However in contrast, several human studies have demonstrated 329 
increased IFN signatures in asthmatic children with virus infections, as well as in severe asthma 330 
in adults;45-47 these might represent different disease states, as a recent report found that early 331 
life exacerbation-prone asthma was correlated with low IFN signatures, while the highest IFN 332 
signatures were associated with later-onset asthma.48 333 
Allergy is a major risk factor for the progression from wheezing illnesses to asthma, and 334 
this has been a very consistent finding across multiple cohorts.21, 49, 50 Allergic sensitization 335 
precedes wheezing illnesses in most young children,42 and allergic inflammation can impair 336 
antiviral responses in vitro51 and in vivo.52 This suggests that allergic airway inflammation can 337 
increase susceptibility to and severity of viral respiratory illnesses. Allergic sensitization in early 338 
childhood may also modify the relationship between microbial colonization and respiratory 339 
outcomes. In preschool children whose airways were colonized with pathogen-dominated 340 
microbiomes, sensitized children were at increased risk for chronic asthma while non-sensitized 341 
children were likely to have transient wheeze that resolved by age 4 years.53 342 
It is well established that hospitalization for RSV bronchiolitis in the first year of life is 343 
associated with later development of asthma.38, 54-56 RSV induces a broad innate immune 344 
response in infants including systemic interferon, neutrophil, and inflammatory pathways, and 345 
distinct RSV strains and concomitant airway bacteria can influence the severity of infection.57, 58 346 
The risk for more severe RSV-illnesses has also been linked to polymorphisms in several 347 
immune regulatory genes,59 many of which also can influence asthma risk. However, whether 348 
RSV is causal remains a subject of debate with two large cohort studies showing different 349 
conclusions,59, 60 one suggesting causation and the other an underlying genetic predisposition. 350 
Notably, two prevention studies using palivizumab (a monoclonal antibody directed against 351 
RSV) in high-risk infants found that prevention of more severe RSV-illnesses decreased the risk 352 
of childhood recurrent wheezing but not asthma development.61, 62 Ultimately RSV infection 353 
appears to have the greatest impact on asthma risk during a critical window of lung 354 
development for infants born during the fall (in the Northern hemisphere) who are at ~4 months 355 
of age during the peak of the winter RSV season. It has been well-established that RSV 356 
infection can induce pathologic Th2 immune responses, especially within the context of 357 
formalin-inactivated RSV vaccination.63-65 More recently, studies in mice have demonstrated the 358 
ability for RSV-related Pneumonia Virus of Mice as well as human RSV infection to break 359 
tolerance to allergens in neonatal mice.66 Furthermore, it is now appreciated that RSV triggers 360 
release of epithelial-derived cytokines that promote Th2 responses and can induce ILC2 361 
responses following infection.67, 68 These same epithelial cytokines have also been implicated in 362 
RV infection, perhaps suggesting a shared innate Th2-skewing mechanism during viral 363 
infection.27, 40 364 
Future perspectives: Fully understanding the patterns of immune development that lead to 365 
asthma inception, and how such patterns are affected by exogeneous exposures including viral 366 
infections, will direct asthma prevention research. Ongoing studies are focused on altering Th2-367 
skewing in early life including through blocking IgE and through altering microbial exposures. If 368 
effective, decreasing Th2-inflammation in early life may function in part through enhancing 369 
antiviral responses.51, 69  However, antiviral specific therapies including RV and RSV vaccines, 370 
may also prove to be critical in asthma prevention.  371 
 372 
Dynamics of respiratory tract bacterial colonization during viral upper respiratory tract 373 
infection 374 
Detection of viruses in the upper airway during peak viral seasons can be as high as 375 
90% in prospective studies.70 However, rates of illness are significantly lower, leading 376 
researchers to question why some patients are more susceptible to increased morbidity when 377 
they have a viral upper respiratory tract infection (URI).  One factor that has been shown to 378 
increase upper and lower airway symptoms during viral infections are bacteria.71  379 
These bacteria collectively constitute the microbiota. The upper airway microbiota 380 
develops over the first year of life with alterations in the natural development associated with 381 
increased risk for URIs during the first few years of life.72, 73  The most abundant bacteria within 382 
the upper airway of infants and children are Staphylococcus, Streptococcus, Moraxella, 383 
Haemophilus, Dolosigranulum, and Corynebacterium.71, 72, 74-78   384 
In several infant cross-sectional and cohort studies, the presence of Streptococcus, 385 
Moraxella, or Haemophilus during upper respiratory infection increases the likelihood that the 386 
infant will have lower airway symptoms.72, 76 Studies examining airway bacteria during RSV 387 
bronchiolitis have reported links between an increased abundance of Streptococcus9 and 388 
Haemophilus.78 In contrast, RV-bronchiolitis is associated with an increased abundance of 389 
Moraxella and Haemophilus.9 While these studies suggest that a bacteria-virus interaction 390 
occurs during infancy, only a few studies have examined the association between virus and 391 
bacteria in school-age children. One such study revealed that children with Streptococcus or 392 
Moraxella present in their airway are more likely to have cold and asthma symptoms during a 393 
naturally occurring RV infection.71 Collectively, these studies demonstrate that an association 394 
exists between specific bacteria and illness severity.  395 
While Streptococcus, Moraxella and Haemophilus are often associated with an increase 396 
in viral-associated symptoms, a higher abundance of Corynebacterium, Staphylococcus and 397 
Dolosigranulum is often present in the airway in the absence of viral detection and clinical 398 
symptoms.75, 77, 78 In addition, when the latter three bacteria are enriched in the upper airway, 399 
infants are less likely to have an acute respiratory illness,72 and school-age children are less 400 
likely to have a symptomatic illness during RV infection.75 Furthermore, high abundance of 401 
Lactobacillus in the upper airway during RSV illness is associated with a decreased risk of 402 
childhood wheeze,77 suggesting that bacteria present in the airway during viral illnesses may 403 
contribute to both illness severity and long term sequela. 404 
Future perspectives: Because most studies examining airway bacteria during viral infection 405 
have been cross-sectional, observational studies, it remains unclear how airway microbes affect 406 
the epithelium, and whether these interactions contribute to the causation of wheezing illnesses, 407 
asthma development in young children, and exacerbations of established asthma. Greater 408 
insight is needed into metabolic, immunologic and toxic effects of bacteria on epithelial cells that 409 
could contribute to acute illnesses and asthma risk. While many studies have examined 410 
changes in bacteria that occur during viral infection, few have examined how the airway 411 
microbiome influences susceptibility vs. resilience to viral infection. Some bacteria could 412 
promote a “pro-inflammatory” environment thereby making the airway susceptible to viral 413 
infection. The presence of H. influenzae in the infant airway prior to viral infection is associated 414 
with increased expression of local inflammatory cytokines suggesting a link between bacteria 415 
and airway inflammation.79 In contrast, mice receiving intranasal administration of Lactobacillus 416 
rhamnosus prior to viral infection have enhanced antiviral immune responses,80 suggesting that 417 
some bacteria protect the airway and reduce the risk of symptomatic viral infection. Greater 418 
understanding of these relationships may lead to new preventive approaches to acute viral-419 
bacterial illnesses and perhaps the development of childhood asthma.  420 
 421 
The influence of the gut microbiome on viral infections of the respiratory tract 422 
The gut microbiome represents the most abundant and diverse microbial environment in 423 
the human body, comprised of approximately 40 trillion bacteria.81  These bacteria have 424 
coevolved with humans over millennia to contribute to a symbiosis in which humans consume 425 
prebiotic fiber which is metabolized by resident microbes in the gut to create short chain fatty 426 
acids (SCFA) which in turn regulate immune responses.82, 83  Alterations in this relationship are 427 
occurring in modern times due to practices such as the frequent use of antibiotics, and the 428 
consumption of a high-sugar, low fiber diet.  As a consequence,  a state of microbial dysbiosis, 429 
or an ecological imbalance, may result, which leads to the loss of metabolic capabilities and 430 
predisposes infants to both the development of atopic diseases as well as an increased 431 
susceptibility to viral infections.84  432 
 Although epidemiologic evidence strongly supports a role of the gut microbiome in the 433 
development of asthma, the mechanisms remain unclear.85, 86   The most popular theory to 434 
explain these observations is that colonization with certain gut bacteria have a direct anti-435 
inflammatory effect on the respiratory tract decreasing the likelihood of airway hyperreactivity.87  436 
However, there is evidence that certain species of microbiota in the gastrointestinal tract prime 437 
the respiratory immune system to effectively fight viral pathogens.  Immunologic factors in early 438 
life such as low blood cell interferon responses88-91 and attenuated cytokine production92 have 439 
been associated with increased risk for wheezing in infancy. Furthermore, patterns of 440 
metabolites (which can regulate immune responses93) at birth are associated with the risk for 441 
wheezing illnesses.94 The idea that delayed immune maturation might contribute to wheezing is 442 
supported by studies showing that early life exposures to dogs,95, 96 farm life,10, 97 and increased 443 
microbes and allergens98 are inversely related to the risk of wheezing illnesses. Furthermore, 444 
exposure to these microbes and allergens during the prenatal period or infancy may be 445 
immunostimulatory.99, 100 A loss, therefore, of these resident microbes may then lead to a 446 
predisposition to viral infections and in turn, the development of asthma. 447 
Several studies have proposed mechanisms for the influence of the gut microbiota on 448 
both local and distant immune functions.  SCFA have been shown to have a local effect on 449 
immune responses through their influence on mucosal barrier function, and a loss of SCFA-450 
producing bacteria has been implicated in the development of food allergy.101  Recent advances 451 
have also shown that this symbiosis also influences vital immune responses in other systemic 452 
tissues.  For example, in the absence of SCFA, mucosal barrier function can break down and 453 
allow for translocation of gut pathobionts, bacteria that are symbiotic under normal conditions 454 
but pathogenic when removed from their normal environment, which, in turn, can drive 455 
autoimmunity.102  Similarly, in a murine model intact commensal bacteria in the gut were 456 
required for adaptive immune responses to respiratory influenza virus infection.  Specifically, 457 
when mice were treated with antibiotics, they had reduced virus-specific antibody titers, CD4+ 458 
T-cell responses, and cytokine secretion which consequently resulted in elevated viral titers post 459 
infection.  This impairment, however, was rescued by local or distal injection of Toll-like receptor 460 
ligands.103  Further, exposure to house dust from homes with dogs enriched the cecal 461 
microbiome in a murine model with L. johnsonii, which protected them against infection with 462 
RSV.104   463 
Future Perspectives: Although the pathways remain incomplete, evidence continues to mount 464 
that the gut microbiome can influence the maturation of the immune system in viral defense and 465 
therefore the development of asthma.105  Future therapies look to a role of probiotics for the 466 
prevention and treatment of allergic disorders, with recent evidence that atopy risk may be 467 
associated with a dysbiosis of the gut microbiome. Studies have shown that in asthma, MMP9 468 
(members of a family of enzymes that cleave extracellular matrix proteins) levels were 469 
significantly increased and treatment with the probiotic, L. rhamnosus GG (LCC), decreased 470 
MMP9 expression in lung tissue and inhibited inflammatory cell infiltration, as well as reducing 471 
exhaled nitric oxide among 4- to 7-year olds in pediatric asthma.106 472 
In early childhood, total fecal IgE levels appear to be specifically correlated with house dust 473 
mite-specific IgE levels, indicating that fecal IgE levels represent markers of allergic response to 474 
aeroallergens.  A significant correlation of fecal IgE levels with Dorea spp. and Clostridium spp. 475 
related to allergic rhinitis and asthma, respectively, suggest that modulation of particular subsets 476 
of gut microbial dysbiosis could contribute to the susceptibility to allergic airway diseases.107  477 
Future work is required for identification of specific species and functional studies to understand 478 
the strength and mechanism of these associations.  In the future, it is critical to understand more 479 
precisely the microbiota composition.  Optimized biomarker studies of the microbial taxa and the 480 
metabolites involved in asthma-associated dysbiosis could help identify infants at risk of asthma 481 
before symptoms.  This would also provide a scientific rationale for future therapeutic strategies 482 
aimed at restoring an altered infant gut microbiome. Future studies need to revolve around 483 
state-of-the-art methods for the evaluation of the microflora to better define indications, the 484 
probiotic strains and the type of prebiotic to be used. 485 
 486 
Potential for primary prevention: clinical trials aiming to prevent the development of the 487 
episodic wheeze phenotype 488 
The inception of childhood asthma is tightly related to early life events such as 489 
respiratory infections and the development of aeroallergens sensitization. Other co-factors (e.g., 490 
vitamin D) may modulate asthma inception pathways. Previous and on-going clinical trials, 491 
geared for asthma prevention, have targeted these pathways and co-factors. 492 
Early life respiratory infections are significant determinants of childhood asthma108. In 493 
young toddlers, prevention of severe RSV bronchiolitis may reduce the risk of episodic 494 
wheeze/asthma development 109, 110. In preterm infants (33-35 wks), palivizumab treatment 495 
during the RSV season resulted in a 73% reduction in the number of wheezing days during the 496 
first year of life, and outside of the RSV season109. A follow up study from the same cohort, 497 
revealed that at the age of 6 years the intervention resulted in a 41% relative risk reduction in 498 
parent-reported asthma, but the forced expiratory volume in 0.5 s (FEV0.5) percentage predicted 499 
values, which was an additional primary outcome, were similar between the palivizumab and 500 
placebo treated infants110. 501 
Since early life respiratory infections cannot be completely prevented, attenuation of the 502 
immune/inflammatory processes during these infections may be another pathway for asthma 503 
prevention. This concept is illustrated by the results of a proof-of concept clinical trial in 40 504 
infants hospitalized with RSV bronchiolitis. In this trial, azithromycin treatment for 2 weeks, 505 
during acute RSV bronchiolitis, reduced the likelihood of developing recurrent wheeze during 506 
the subsequent year111. Azithromycin effects were attributed to anti-inflammatory properties 507 
and/or its effects on the airway microbiome112. A larger confirmatory trial is ongoing (APW-RSV 508 
II; NCT02911935; Table 3). 509 
Based on observational studies that linked maternal vitamin D deficiency to childhood 510 
asthma, two clinical trials (VDAART113, COPSAC2010114) investigated whether maternal vitamin 511 
D supplementation (2400 IU/day113, 4000IU/day114) during pregnancy would prevent 512 
asthma/recurrent wheeze in their children. A recent meta-analysis that combined these two 513 
trials revealed that this intervention resulted in a 25% significant reduction in asthma/recurrent 514 
wheeze risk during the first 3 years of life 115. The effect was most profound among women with 515 
sufficient serum vitamin D levels at randomization highlighting the importance of normal pre-516 
conception vitamin D levels115. It was suggested that vitamin D beneficial effects may be related 517 
to enhancement of in-utero lung growth and development and promotion of antimicrobial effects, 518 
thereby reducing early life respiratory infections, and/or providing immune modulation effects 116. 519 
Omega-3 fatty acids were suggested to have anti-inflammatory effects, potentially due to 520 
decreased production of arachidonic acid metabolites. In a recent clinical trial, high dose 521 
Omega-3 fatty acids supplementation (2.4 g daily) to pregnant women, beginning at 24 week of 522 
gestation, resulted in a 30% relative risk reduction of persistent wheeze or asthma at age 3 523 
years117. These positive effects were driven by subgroups of children born to mothers with a 524 
variant of the gene encoding fatty acid desaturase, predisposing to low ability to produce 525 
omega-3 fatty acids, and by infants born to mothers with low omega-3 fatty acids baseline blood 526 
levels. These sub-group analyses suggest the plausibility of a precision-medicine approach of 527 
this potential future intervention. Nevertheless, it is important to assure that high dose omega-3 528 
fatty acids does not possess any safety issues, before omega-3 fatty acids may be utilized for 529 
asthma prevention. 530 
The ongoing ORBEX clinical trial (NCT02148796) is attempting to modulate the infant 531 
immune system by treating high-risk preschool children with Broncho-Vaxom® for 2 years to 532 
prevent/delay the development of wheezing lower respiratory tract illness (WLRI) during a third 533 
observation year.  Broncho-Vaxom® contains bacterial lysates and was previously shown to 534 
reduce the rate of respiratory infections118. Hence, it is postulated that prevention of early life 535 
WLRI will prevent the development of the recurrent wheeze phenotype.  Finally, the ongoing 536 
PARK clinical trial (NCT02570984) is targeting the association between allergic sensitization 537 
and asthma inception. PARK investigates whether treatment of high-risk preschool children with 538 
Omalizumab for 2-years would prevent asthma development, and whether the treatment would 539 
decrease asthma severity among infants who will develop asthma, during an additional 2-year 540 
observation period. 541 
Future perspectives: This is an exciting time for all involved in childhood asthma prevention: 542 
recent clinical trials have shown the feasibility of asthma prevention, and multiple clinical trials 543 
are ongoing toward this goal. In addition to targeting type 2 immune responses, new 544 
interventions are needed to inhibit viral replication, either with specific inhibitors or strategies to 545 
boost the development of global antiviral responses in the airways. Finally, studies in farming 546 
environments strongly suggest that environmental exposure can lower the risk of viral 547 
respiratory illness in addition to reducing allergy.10, 97 Identifying relevant mechanisms is likely to 548 
lead to new preventive approaches to virus-induced wheeze and asthma. 549 
 550 
New therapeutic options to decrease severity of asthma exacerbations caused by 551 
respiratory viral infection  552 
Recent studies have focused on short-term increases in standard asthma therapy, 553 
vitamin D supplementation, azithromycin and anti-IgE therapy.  However, mixed efficacy results 554 
limit the widespread application of many of these therapies in clinical practice. 555 
Maintenance inhaled corticosteroids (ICS) are effective in reducing the risk of asthma 556 
exacerbations and, when combined with inhaled long acting beta agonists (LABA), this 557 
decreases the risk further.  However, exacerbations continue to occur.  Attempts to increase 558 
dosing of inhaled steroid with early signs of loss of asthma control with viral infection, termed 559 
the “yellow zone”, to decrease exacerbation risk, have yielded mixed results. GINA guidelines 560 
suggest increasing ICS at onset of symptoms as part of a self-management plan 561 
(http://www.ginasthma.org). A Cochrane database review (including five studies in adults and 562 
three studies in children) concluded that current evidence does not support increasing ICS in 563 
mild to moderate asthma patients as part of a self-management plan to treat exacerbations.119 564 
A clinical trial examined this question further in 254 children aged 5-11 with history of 565 
mild to moderate persistent asthma with at least one previous exacerbation in the past year.120 566 
Children were treated for 48 weeks with low dose inhaled steroid and assigned to either 567 
continue this or quintuple the dose for 7 days at onset of loss of asthma control. There was no 568 
significant difference in the rate of severe exacerbations in the groups.  The total corticosteroid 569 
exposure in the high dose group was 16% higher (including both inhaled corticosteroid use and 570 
prednisone) and there was an effect on linear growth velocity between the high dose and low 571 
dose group (-0.23 cm/year), suggesting potential risk without identifiable benefit of the therapy.  572 
Vitamin D levels have been inversely associated with asthma severity, including 573 
hospitalization for severe infections.121  A large study aimed at optimizing low Vitamin D levels 574 
through supplementation did not reduce rates of colds or treatment failures in adults with 575 
asthma.122, 123 In contrast, a meta-analysis of seven randomized trials demonstrated a significant 576 
reduction in asthma exacerbations, with the effect seen only in patients with low vitamin D at 577 
baseline.124 There are ongoing studies in children with asthma examining the possible role of 578 
vitamin D supplementation in preventing asthma exacerbations (Table 3). 579 
Current guidelines do not recommend the use of antibiotic treatment for episodes of 580 
asthma-like symptoms in children, yet they are commonly used.  A randomized, double-blind, 581 
placebo-controlled trial conducted in the US, evaluated the role of early administration of 582 
azithromycin in prevention of progression to severe lower respiratory tract illness (LRTI) 583 
symptoms.125   Preschool children, age 12-71 months, with history of recurrent severe wheezing 584 
in the setting of LRTI, were randomized to azithromycin 12 mg/kg for 5 days (307 patients) or 585 
placebo (300 patients).  The medications were to be started as soon as the children developed 586 
signs or symptoms that typically preceded the development of a severe LRTI.  The primary 587 
outcome measure was the number of respiratory tract infections not progressing to a severe 588 
LRTI. The azithromycin group experienced a lower risk of progression to a severe LRTI than the 589 
placebo group.   590 
In the COPSAC2010 (Copenhagen Prospective Studies on Asthma in Childhood 2010 591 
cohort), children (age 1-3) with recurrent asthma-like symptoms within this cohort were enrolled 592 
in a study to assess the duration of episodes when treated with azithromycin.126  With each 593 
episode of 3 days of consecutive symptoms (wheeze, cough, dyspnea), children were 594 
randomized to receive 10 mg/kg azithromycin or placebo for 3 days.  Seventy-two children from 595 
the recurrent asthma-like symptoms group had 158 episodes.  The azithromycin treatment 596 
shortened the days of symptoms, 3.4 days compared with 7.7 days after placebo, 597 
corresponding to a calculated reduction in episode length of 63.3%.  More improvement was 598 
seen when the treatment was started earlier in the episode; however, treatment did not 599 
significantly affect the time to next episode of troublesome lung symptoms in children. 600 
With these episodes, a hypopharyngeal aspirate was collected and cultured for common 601 
bacterial pathogens and a nasopharyngeal aspirate was collected for viral PCR.  Overall, the 602 
presence of any cultured pathogenic bacteria did not significantly alter the treatment effect 603 
compared to episodes without bacteria present; however, azithromycin was more effective in 604 
those whose culture grew H. influenzae.  The treatment effect in these studies is promising; 605 
however, resistance to these antibiotics and eliminating commensal microbes along with 606 
pathogens are concerns with repeated treatment.   607 
Birth cohort studies have shown allergic sensitization to be a risk factor for RV-induced 608 
wheeze.42  Additionally, in one prospective cohort study, the severity of RV-triggered asthma 609 
exacerbation increased as the degree of allergen sensitization increased, with serum IgE levels 610 
(total IgE and allergen specific IgE) increasing from baseline during the exacerbation.127  611 
Persistence of asthma by age 13 was most strongly associated with wheezing illness with RV 612 
and aeroallergen sensitization in early life37 suggesting a role for both viral infection and allergic 613 
sensitization in the development of asthma.   614 
A possible mechanism for impaired response to viral infections in allergic asthmatics is a 615 
decreased secretion of IFN in response to viral infection.  Purified plasmacytoid dendritic cells 616 
(pDC) from patients with allergic asthma were shown to secrete less IFN-α in response to 617 
exposure with influenza A virus.51  Increased FcεRIα expression and serum IgE levels were 618 
inversely associated with IFN- α secretion.  The increased susceptibility to viral wheeze in atopic 619 
patients and impaired antiviral response in these patients suggests a role for possible 620 
therapeutic intervention to decrease allergic inflammation with the goal of decreasing asthma 621 
exacerbations in response to viral infection.    622 
Omalizumab, a humanized monoclonal antibody that selectively binds to IgE, has 623 
recently been studied as an add-on therapy to prevent fall asthma exacerbations in atopic 624 
asthmatics in the Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations 625 
(PROSE) study.128  The PROSE study included 478 children, age 6-17, with respiratory allergy 626 
and asthma, randomized to either inhaled corticosteroid boost, add on omalizumab or placebo.  627 
All patients had guidelines-based care in addition to the add-on treatment (ICS boost, 628 
omalizumab or placebo).  Treatment was begun 4-6 weeks before the participant’s school start 629 
day and ended 90 days after school start date.   Omalizumab treatment significantly decreased 630 
the odds of having at least 1 exacerbation, whereas boosting ICS did not reduce risk. 631 
Omalizumab increased IFN-α responses to RV ex vivo.  Within the omalizumab group, greater 632 
restoration of IFN-α responses were associated with fewer exacerbations.  In this trial, 633 
omalizumab was associated with a decreased frequency of RV illnesses, decreased duration of 634 
RV infection as well as decreased frequency of overall respiratory illness, and reduced peak RV 635 
shedding.52  Omalizumab reduced expression of FcεRIα on the surface of pDC and this 636 
reduction was associated with lower exacerbation rates and correlated with enhanced IFN-α 637 
production, suggestion a possible mechanism for the interaction between allergic sensitization 638 
and virus-induced asthma exacerbations.69  However, the connection between the pDC type I 639 
IFN production and asthma exacerbation will benefit from further study. 640 
In an observational study following children with asthma presenting with an acute 641 
asthma exacerbation triggered by RV, the use of omalizumab for at least 4 weeks prior to 642 
presentation was associated with reduced severity of exacerbation compared with patients 643 
primarily treated with ICS.129    This suggests a benefit in not only frequency and duration of 644 
asthma exacerbation, but also severity of exacerbation.  645 
Another possible mechanism for the interaction between allergic sensitization and virus-646 
induced asthma exacerbations is the presence of anti-viral IgE in response to infection.  In RSV 647 
infection in infants, RSV specific IgE was detected in nasopharyngeal secretions, with 648 
significantly higher titers in subjects with wheezing.130, 131 Correlation of the peak titers with 649 
degree of hypoxia was also noted.  Following known exposure to a specific laboratory strain, 650 
RV-specific IgE could be detected in human sera.132  While the IgE response to RV and RSV 651 
are associated with infection, the role of IgE in the host response to these infections is not fully 652 
understood.  Given the decreased exacerbations with use of omalizumab, further investigation 653 
into the role of anti-viral IgE is indicated.  654 
Future perspectives:  Given the morbidity of RSV and RV infections in patients with asthma, a 655 
consistent and effective treatment approach is highly desirable.  While studies have found 656 
possible benefits to treatment with azithromycin and omalizumab, the widespread use of these 657 
treatment approaches is not currently justified.  Further characterization of risk in this patient 658 
population and additional work to delineate the mechanisms by which these drugs are effective 659 





There have been important advances in our knowledge of the relationship between viruses and 665 
asthma over the last decade.  Advances in scientific methods have provided innovative 666 
opportunities to examine host, environment, and viral interactions that either protect against or 667 
increase vulnerability to asthma development and exacerbations.  The exploration of the 668 
contribution of the respiratory and gut microbiome to virally-induced asthma is in its infancy and 669 
we suspect that over the next 5 years there will be major advances in this area.  Finally, primary 670 
prevention is a major goal to diminish the morbidity of virally-mediated wheezing, asthma and 671 
exacerbations.  Until primary prevention becomes a reality, clinical trials examining the impact of 672 
established medications, as well as novel therapies, will be critical to diminish the impact of viral 673 
infections on wheezing and asthma. 674 
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  1069 
 1070 
Table 1. Review of most salient points 1071 
 1072 
1.  Polymorphisms in several antiviral and innate immune genes have been linked to 1073 
susceptibility to respiratory viruses, infection severity, and virus-induced asthma exacerbations, 1074 
and have been replicated across multiple cohorts; these genes include STAT4, JAK2, MX1, 1075 
VDR, DDX58, and EIF2AK2. 1076 
 1077 
2.  Rhinovirus virulence varies by species; RV-A and RV-C are more likely to cause illnesses, 1078 
wheezing and lower respiratory tract infection compared to RV-B. 1079 
 1080 
3.  RV infection leads to expression of epithelial derived cytokines IL-25, IL-33, and TSLP and 1081 
an increase in ILC2s as an important source of airway IL-13; blocking these pathways with anti-1082 
IL-25 attenuates neonatal RV-induced AHR and mucous cell metaplasia in mice. 1083 
 1084 
4.  Two prevention studies using palivizumab (a monoclonal antibody directed against RSV) in 1085 
high-risk infants found that prevention of more severe RSV-illnesses decreased the risk of 1086 
childhood recurrent wheezing but not asthma development. 1087 
 1088 
5.  In several infant cross-sectional and cohort studies, the presence of Streptococcus, 1089 
Moraxella, or Haemophilus during upper respiratory infection increases the likelihood that the 1090 
infant will have lower airway symptoms; studies examining airway bacteria during RSV 1091 
bronchiolitis have reported links between an increased abundance of Streptococcus and 1092 
Haemophilus, while in contrast, RV-bronchiolitis is associated with an increased abundance of 1093 
Moraxella and Haemophilus. 1094 
 1095 
6.  The presence of H. influenzae in the infant airway prior to viral infection is associated with 1096 
increased expression of local inflammatory cytokines suggesting that a link exists between 1097 
bacteria and airway inflammation; in contrast, mice receiving intranasal administration of 1098 
Lactobacillus rhamnosus prior to viral infection have an enhanced antiviral immune response80, 1099 
suggesting that some bacteria may protect the airway and help prevent viral infection. 1100 
 1101 
7.  The gut microbiome also regulate pulmonary anti-viral immunity; in a murine model intact 1102 
commensal bacteria in the gut were required for adaptive immune responses to respiratory 1103 
influenza virus infection. 1104 
 1105 
8.  Unique components of the viral genome contribute to respiratory illness and knowledge of 1106 
these factors may also assist in vaccine and therapeutic strategies aimed at the proteins 1107 
responsible for specific disease characteristics. 1108 
 1109 
9.  Omalizumab, a humanized monoclonal antibody that selectively binds to IgE, decreased fall 1110 
asthma exacerbations in atopic asthmatics and increased IFN-α responses to RV ex vivo in the 1111 
Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations (PROSE) study, whereas 1112 
boosting ICS did not reduce risk.  1113 
 1114 
10.  A recent meta-analysis that combined two clinical trials (VDAART, COPSAC2010) 1115 
investigated whether maternal vitamin D supplementation (2400 IU/day, 4000IU/day) during 1116 
pregnancy revealed that this intervention resulted in a 25% significant reduction in 1117 
asthma/recurrent wheeze risk during the first 3 years of life. 1118 
 1119 
Table 3. Future/ongoing interventional studies examining treatments for viral triggered 1120 
asthma  1121 
  1122 
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Figure 1. Immune responses to virus in the allergic asthmatic host. In the healthy host, anti-viral 1123 
IFN responses control and clear respiratory viral infections. In allergic asthmatics, the release of 1124 
the type 2-skewing cytokines TSLP, IL-25, and IL-33 promote the induction of Th2 cytokines 1125 
and the suppression of IFN responses, in addition to promoting airway hyperreactivity (AHR) 1126 
and increased mucus and IgE production. Furthermore, IgE has the capacity to suppress IFN-α 1127 
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commensal bacteria in the gut were required for adaptive immune responses to respiratory 
influenza virus infection. 
 
8.  Unique components of the viral genome contribute to respiratory illness and knowledge of 
these factors may also assist in vaccine and therapeutic strategies aimed at the proteins 
responsible for specific disease characteristics. 
 
9.  Omalizumab, a humanized monoclonal antibody that selectively binds to IgE, decreased fall 
asthma exacerbations in atopic asthmatics and increased IFN-α responses to RV ex vivo in the 
Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations (PROSE) study, whereas 
boosting ICS did not reduce risk.  
 
10.  A recent meta-analysis that combined two clinical trials (VDAART, COPSAC2010) 
investigated whether maternal vitamin D supplementation (2400 IU/day, 4000IU/day) during 
pregnancy revealed that this intervention resulted in a 25% significant reduction in 
asthma/recurrent wheeze risk during the first 3 years of life. 
 
Table 2.  Polymorphisms in several antiviral and innate immune genes have been linked to susceptibility to respiratory viruses, infection severity, 
and virus-induced asthma exacerbations, and have been replicated across multiple cohorts. 
 
Gene  Function 
STAT4   Transcription factor required for IL-12 signaling in the development of Th1 cells from naïve CD4 T cells 
JAK2  A non-receptor tyrosine kinase critical for signaling of the GM-CSF, gp130, and single chain receptor families. 
MX1  Responsible for the antiviral state against influenza infection 
VDR  Vitamin D receptor 
DDX58   Involved in antiviral signaling in response to viruses containing a dsDNA genome 
EIF2AK2 Innate antiviral immune response to viral infection that can trigger apoptosis via FADD-mediated caspase 8 
IRF7  Critical role in the innate immune response against DNA and RNA viruses 
IFIH1  Provides instructions for making the MDA5 protein that has a critical role in innate antiviral immunity 
IFNA5  One of the type I IFN-α isoforms that has antiviral activities 
NOS2  Nitric oxide synthase gene that mediates the antiviral activity of IFN-γ 
ADAM33 Member of the ADAM (a disintegrin and metalloprotease domain) family identified as a major susceptibility gene in asthma  
IL4R  Interleukin 4 receptor through which IL-4 and IL-13 signal to induce IgE class switching and airway mucus metaplasia 
CD14  Multiple functions, one of which is critical for TLR signaling in host defense 
TNF  Tumor necrosis factor that is produced in abundance by mast cells and has roles in cell survival and proliferation 
IL13  Important in airway mucous cell metaplasia, airways responsiveness, VCAM expression 
IL1RL1  One subunit of the receptor for IL-33, which can activate ILC2 and promote CD4 T cell differentiation toward Th2 phenotype 
CDHR3  Cadherin that is the receptor for rhinovirus 
 
Table 3. Future/ongoing interventional studies examining treatments for viral triggered 
asthma  
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